Table 5.

Comparison of eflornithine monotherapy treatment (in the NECT clinical trial,⁷,⁸ and during routine use in the Ibba MSF treatment Centre, South Sudan),²⁰ and NECT (in the NECT clinical trial⁷,⁸ and in routine use as monitored by WHO)

	Eflornithine				NECT
	NECT clinical trial		Control program Ibba (S. Sudan)		NECT clinical trial		Routine use PV system
	n	%	n	%	n	%	n	%
Cases treated (n)	143		1055		143		1735
Cases with at least one AE	134	93.7	962	91.2	134	93.7	1043	60.1
Cases with major clinical AE	33	23.1	138	13.1	18	12.6	189	10.9
Cases with SAE	6	4.2			1	0.7	19	1.1
Cases requiring treatment interruption	9	6.3	109	10.3			45	2.6
Deaths during treatment	3	2.1	16	1.5	1	0.7	9	0.5

Abbreviations: AE, adverse event; MSF, Médecins Sans Frontières; NECT, nifurtimox-eflornithine combination therapy; SAE, serious adverse event; WHO, World Health Organization.